Paid Clinical Trials Portland
Discover 165 paid clinical trials in Portland, Maine. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass SurgeryEffect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
Sponsor:
Unity Health Toronto
Location:
Code:
NCT03900026
Conditions
Coronary Artery Bypass Graft Surgery
Atherosclerosis
Vein Occlusion
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Evolocumab
Placebo
A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)
Sponsor:
Boston Children's Hospital
Location:
Code:
NCT05600426
Conditions
Severe Aplastic Anemia
Eligibility Criteria
Sex: All
Age: 0 - 25
Healthy Volunteers: Not accepted
Interventions
cyclosporine
Matched Unrelated Donor Hematopoetic Stem Cell Transplant
horse anti-thymocyte globulin (ATG)
rabbit anti-thymocyte globulin (ATG)
Methotrexate
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT06065748
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Giredestrant
Fulvestrant
Abemaciclib
Palbociclib
Ribociclib
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast CancerOpen-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
Sponsor:
Stemline Therapeutics, Inc.
Location:
Code:
NCT05563220
Conditions
Breast Cancer
Metastatic Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Elacestrant
Alpelisib
Everolimus
Ribociclib
Palbociclib
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaSelinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Sponsor:
Karyopharm Therapeutics Inc
Location:
Code:
NCT05611931
Conditions
Endometrial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Selinexor
Matching Placebo for selinexor
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE TrialDeveloping an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial
Sponsor:
Wake Forest University Health Sciences
Location:
Code:
NCT06216574
Conditions
Breast Cancer Female
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Internet-based Intervention
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaThoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Sponsor:
Children's Oncology Group
Location:
Code:
NCT05235165
Conditions
Metastatic Malignant Neoplasm in the Lung
Metastatic Osteosarcoma
Osteosarcoma
Eligibility Criteria
Sex: All
Age: 0 - 50
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Questionnaire Administration
Thoracoscopy
Thoracotomy
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGAnticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Sponsor:
Icahn School of Medicine at Mount Sinai
Location:
Code:
NCT04045665
Conditions
Atrial Fibrillation
Stroke
Bleeding
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Antiplatelet-only strategy
Oral Anticoagulant plus background antiplatelet therapy
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Sponsor:
AstraZeneca
Location:
Code:
NCT05952557
Conditions
Breast Cancer, Early Breast Cancer
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Camizestrant
Tamoxifen
Anastrozole
Letrozole
Exemestane